RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develops and sells products for some of our most common diseases in wound and dental care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
 RLS Global's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS Global intends to work with partners to commercialize products globally. RLS Global is convinced that the company's platform technology and its unique features will help many patients around the world. RLS Global is listed on the Nasdaq First North Growth Market and trading takes place under the short name RLS. Read more at www.rls.global Product website: chlorasolvacademy.se